In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

Shio-Shin Jean,1,2 Min-Chi Lu,3 Zhi-Yuan Shi,4 Shu-Hui Tseng,5 Ting-Shu Wu,6 Po-Liang Lu,7 Pei-Lan Shao,8 Wen-Chien Ko,9 Fu-Der Wang,10,11 Po-Ren Hsueh12,13 1Department of Emergency Medicine and Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 2Depa...

Cijeli opis

Spremljeno u:

Bibliografski detalji
Glavni autori:	Jean SS, Lu MC, Shi ZY, Tseng SH, Wu TS, Lu PL, Shao PL, Ko WC, Wang FD, Hsueh PR
Format:	Artigo
Jezik:	Inglês
Izdano:	Dove Medical Press 2018-10-01
Serija:	Infection and Drug Resistance
Teme:	Enterobacteriaceae Neisseria gonorrhoeae extended-spectrum β-lactamases carbapenemase ceftolozane-tazobactam ceftazidime-avibactam
Online pristup:	https://www.dovepress.com/in-vitro-activity-of-ceftazidimendashavibactam-ceftolozanendashtazobac-peer-reviewed-article-IDR
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

In vitro activity of ceftazidime&ndash;avibactam, ceftolozane&ndash;tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

Slični predmeti

In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)